Mebendazole-Treated Human Monocyte-Derived Dendritic Cells Represent Promoted Immunogenic Phenotype with Augmented Expression of Inflammatory Markers. (2025)

Peer-Reviewed Study · Shiva Alipour; Sepideh Sohrabi; Amirhossein Mardi et al. · November 2025

Shiva Alipour et al., 2025-11: Study of human monocyte-derived dendritic cells showing mebendazole shifts them towards an immunogenic, inflammatory phenotype with lower IL-10 and IDO.

MBZ-moDCs exhibited increased interleukin (IL)-12, IL-18, IL-1β, and TNF-α gene levels and decreased IL-10 and IDO

Shiva Alipour et al., 2025-11: Study of human monocyte-derived dendritic cells showing mebendazole shifts them towards an immunogenic, inflammatory phenotype with lower IL-10 and IDO. Study type: human monocyte-derived dendritic cells from healthy donors. N: not stated in the abstract. Country: Iran (Tabriz University of Medical Sciences). Dose: not stated in the abstract text captured. Funder: not stated in the record. Declared conflicts: 'The authors declare that there is no conflict of interest.' Comparator: untreated moDCs and LPS-treated moDCs. Study type: lab.